Borean Pharma A

Borean Pharma is a Danish biotechnology company specializing in the development of trimerized protein therapeutics. Founded as a spin-off from Aarhus University, the company focused on engineering proteins that require trimerization for biological activity, particularly targeting the Tumor Necrosis Factor (TNF) superfamily. In 2020, Borean Pharma was acquired by Clover Biopharmaceuticals to bolster Clover's protein-based drug discovery platform and establish a research and development hub in Europe. The company's expertise in protein engineering has been integrated into the development of various vaccine and oncology candidates, including Clover's COVID-19 vaccine and TRAIL-based therapies.